MRTX Overview
Upcoming Projects (MRTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MRTX)
-
Digging into the phase 2 KRYSTAL-7 clinical trial results of adagrasib with pembrolizumab as a treatment for non-small cell lung cancer as presented at ESMO 2023
Tickers: MRTX, MRK
Executed On: Nov 29, 2023 at 01:30 PM EST -
Discussing Mirati's MRTX1719, a MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality, in patients with MTAP deleted cancer
Tickers: MRTX, TNGX
Executed On: Sep 12, 2023 at 03:00 PM EDT -
Examining the potential for Mirati's FDA approved KRAS drug, Krazati (adagrasib) in treating non-small cell lung cancer
Ticker: MRTX
Executed On: Feb 16, 2023 at 03:00 PM EST
Expired Projects (MRTX)
Upcoming & Overdue Catalysts (MRTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MRTX)
-
Phase 2 results for MGCD265 (glesatinib) in non-small cell lung cancer
Ticker: MRTX
Occurred on: Mar 16, 2019 -
Mirati Therapeutics Provides Progress Update On Current Clinical Trials
Ticker: MRTX
Occurred on: Jun 05, 2016
Strategic Initiatives (MRTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
